pilarsato 450 sl herbicide
pilarquim (shanghai) co ltd - glyphosate present as the isopropylamine salt - soluble concentrate - glyphosate present as the isopropylamine salt glycine active 450.0 g/l - herbicide
pilar-2,4-d 625 sl herbicide
pilarquim (shanghai) co ltd - 2,4-d present as the dimethylamine and diethanolamine sa - soluble concentrate - 2,4-d present as the dimethylamine and diethanolamine sa - phenoxy acids-2,4-d - active - 625.0 - g/l - herbicide
pilarmd 250 cs insecticide
pilarquim(shanghai) co., ltd - lambda-cyhalothrin - capsule suspension - lambda-cyhalothrin pyrethroid active 250.0 g/l - insecticide
pilarich 720 sc fungicide
pilarquim(shanghai) co., ltd - chlorothalonil - suspension concentrate - chlorothalonil benzene active 720.0 g/l - fungicide
pilar-alfa liquid
alpha-cypermethrin 10% w/w ec
pilarsato liquid
glyphosate ipa w/w sl 41%
zelboraf
roche products (nz) ltd - vemurafenib 240mg (as a co-precipitate with hypromellose acetate succinate (800 mg total)); ; - film coated tablet - 240 mg - active: vemurafenib 240mg (as a co-precipitate with hypromellose acetate succinate (800 mg total)) excipient: colloidal silicon dioxide croscarmellose sodium hyprolose iron oxide red macrogol 3350 magnesium stearate polyvinyl alcohol purified talc titanium dioxide - indicated for the treatment of unresectable stage iiic or stage iv metastatic melanoma positive for the braf v600 mutation.
zelboraf
roche pharmaceuticals (israel) ltd - vemurafenib - film coated tablets - vemurafenib 240 mg - vemurafenib - vemurafenib - zelboraf is indicated for the treatment of brafv600 mutation-positive unresectable or metastatic melanoma.
mekinist
novartis new zealand ltd - trametinib dimethyl sulfoxide 0.5635mg equivalent to trametinib 0.5 mg; - film coated tablet - 0.5 mg - active: trametinib dimethyl sulfoxide 0.5635mg equivalent to trametinib 0.5 mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose magnesium stearate mannitol microcrystalline cellulose opadry yellow 03b120006 purified water sodium laurilsulfate - mekinist in combination with dabrafenib is indicated for the treatment of patients with brafv600 mutation positive unresectable stage iii or metastatic (stage iv) melanoma. mekinist as a monotherapy is indicated for the treatment of patients with brafv600 mutation positive unresectable stage iii or metastatic (stage iv) melanoma and in whom either there is an intolerance to braf inhibitors or braf inhibitors cannot be used. mekinist as monotherapy has not demonstrated clinical activity in patients who have progressed on braf inhibitor therapy.
mekinist
novartis new zealand ltd - trametinib dimethyl sulfoxide 2.254mg equivalent to trametinib 2 mg; - film coated tablet - 2 mg - active: trametinib dimethyl sulfoxide 2.254mg equivalent to trametinib 2 mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose magnesium stearate mannitol microcrystalline cellulose opadry pink ys-1-14762-a purified water sodium laurilsulfate - mekinist in combination with dabrafenib is indicated for the treatment of patients with brafv600 mutation positive unresectable stage iii or metastatic (stage iv) melanoma. mekinist as a monotherapy is indicated for the treatment of patients with brafv600 mutation positive unresectable stage iii or metastatic (stage iv) melanoma and in whom either there is an intolerance to braf inhibitors or braf inhibitors cannot be used. mekinist as monotherapy has not demonstrated clinical activity in patients who have progressed on braf inhibitor therapy.